Fernanda Raquel Da Silva Andrade Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal). Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Email Fernanda Raquel Da Silva Andrade Email Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Researcher at Drug Delivery and Targeting Group - Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, and is an Associate Professor in the Department of Pharmaceutical Technology from the Faculty of Pharmacy and Food Science from University of Barcelona, Spain. Has a Master in Pharmaceutical Sciences (University of Lisbon, Portugal) and a PhD degree in Pharmaceutical Sciences - Pharmaceutical Technology (University of Porto, Portugal).
Her research interests are based on the development of formulations, namely nanoparticles, for the administration of drugs and biopharmaceuticals (peptides, proteins and genetic material) for the treatment of challenging diseases. Also has experience on study the effects of drugs and delivery systems on cancer stem cells and on the development and use of cell-culture models, animal models, and ex vivo models for drug absorption studies through the pulmonary, intestinal, and blood brain barrier. Her major objective relies on the development of multifunctional drug delivery systems with improved characteristics such as increased therapeutic index and targeted delivery, allowing and efficient and safe treatment of challenging diseases like cancer or infectious diseases, with the ultimate goal of personalized medicine. Her research work at different projects and collaborations with a variety of research groups from different countries have resulted in the authorship of two patents, several research and review papers, as well as book chapters.
Projects Design of Nanoparticles for Blood-Brain-Barrier Crossing and Glioblastoma Multiforme Cancer Stem Cells Targeting (NanoGlio) IP: Ibane Abasolo Olaortua Collaborators: Fernanda Raquel Da Silva Andrade, Miriam Izquierdo Sans Funding agency: Asociación Española Contra el Cáncer Funding: 100000 Reference: INVES211530DASI Duration: 01/09/2021 - 31/08/2025 NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra células madre tumorales IP: Ibane Abasolo Olaortua Collaborators: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 322172.61 Reference: RTC2019-006809-1 Duration: 01/09/2020 - 31/12/2023 Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH IP: María José Buzón Gómez Collaborators: Ibane Abasolo Olaortua, Félix Pumarola Segura, Juan Lorente Guerrero, Laura García Latorre, Jordi Temprana Salvador, Joaquin Seras Franzoso, Marc Pellicer Sarasa, David Perea Pérez, Simon Schwartz Navarro, Jordi Navarro Mercadé, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Judit Grau Exposito, Meritxell Genesca Ferrer, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Funding agency: Fundació La Marató de TV3 Funding: 199998.75 Reference: 20180510 Duration: 10/05/2019 - 31/12/2022 Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados. IP: Ibane Abasolo Olaortua Collaborators: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 116160 Reference: PI18/00871 Duration: 01/01/2019 - 30/06/2022 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page »
